August 2012

Contents

Editorial

• Volume 13 Number 7/8 July/August 2012

Special reports

• AIDS 2012: non-technical conference summaries: HTB supplement

Supplements

• HIV and your quality of life: a guide to side effects and other complications (July 2012)

• i-Base/TAG 2012 pipeline report

Conference reports

• 19th IAS World AIDS Conference, 22–25 July 2012, Washington

• IAS: social and political talks online as web casts

• New booster – cobicistat as an alternative to ritonavir

• Dolutegravir vs raltegravir in treatment-naive patients: 48 week results from the SPRING 2 study

• Elvitegravir vs raltegravir: 96 week phase III results in treatment experienced patients

• In vitro and animal data support safety profile BMS 986001: d4T-like NRTI currently in clinical trials

• Switching to rilpivirine/tenofovir/FTC fixed dose combination from boosted-PI regimen: SPIRIT study draws the line at 24 weeks

• Maraviroc plus atazanavir/ritonavir in a nuke-sparing regimen in treatment-naive patients

• Five-year results from raltegravir registrational studies

• First report: atazanavir-related gallstones (cholelithiasis)

• Paediatrics studies at 19th International AIDS Conference and the 4th International Workshop on HIV Pediatrics

• Novel lopinavir/ritonavir sprinkle formulation for children in resource-limited settings

• Update on new antiretrovirals for children and adolescents

• Tenofovir prophylaxis for neonates

• Efavirenz levels variable in children in the CHAPAS-3 study

• Early initiation of ART is associated with growth recovery in children in NEVEREST-2

• High prevalence of peripheral neuropathy in children taking d4T in rural South Africa

• Lipid profile in children in PREDICT: immediate versus deferred nevirapine-based ART

• High levels of maraviroc in rectal tissue fail to protect macaques from SIV transmission following rectal exposure

• Mechanisms for circumcision to reduce HIV transmission in different penile tissue: target cell differences rather than keratinisation

• Towards an HIV cure: early developments reported

• Important publications launched at IAS 2012

• 14th International Workshop on Co-morbidities and Adverse Drug Reactions (IWCADR), 19–21 July 2012, Washington

• Skeletal muscle toxicity and raltegravir

• Proteinuria as a potential early marker of tenofovir-related renal toxicity

• Earlier and greater comorbidities reported in HIV positive cohort

• 20th International HIV Drug Resistance Workshop, 9–13 June 2012, Sitges

• In vitro resistance profile for BMS 986001

• Recombination dynamics in case of MDR sub-type D following superinfection with wild-type sub-type B

• Defective viral reservoir populations is common in patients on long-term suppressed ART

• First case report of transmission with five-class resistance

• New data on the Berlin patient: interpret with caution

Antiretrovirals

• Dolutegravir indicates superiority compared to efavirenz in treatment-naïve patients: top-line results only

• FDA update to darunavir label: severe skin reactions

Treatment access

• FDA approval of generic ARVs

• Activists protest at IAS for Global Fund to stick to principles

• EU parliament rejects anti-counterfeiting trade agreement: allows continued access to generic medicines

• US trade deal threatens access to medicines

Side effects

• Theratechnologies withdraw EU application for tesamorelin (Egrifta)

• Recent studies on HIV, ART and osteoporotic fracture risk

HIV prevention and transmission

• FDA approve Truvada to reduce the risk of sexual transmission

Basic science and immunology

• Role of cell-to-cell transmission in sustaining the HIV reservoir

Book and film reviews

• ACT-UP in film: ‘How to survive a plague’ and ‘United in anger’

On the web

• PLoS Medicine (July 2012)

PDFs

• Volume 13 Number 7/8 July/August 2012 PDF